Ponomareva A A, Rykova E Iu, Cherdyntseva N V, Choĭnzonov E L, Laktionov P P, Vlasov V V
Mol Biol (Mosk). 2011 Mar-Apr;45(2):203-17.
The major approaches to different lung cancer marker development are outlined in the review, including genetic, epigenetic, protein, transcryptomic, proteomic, metabolic, and miRNA markers. As far as epigenetic changes are among the earliest events in malignant transformation, methylated markers are thoroughly discussed. Special attention is given to minimally invasive tumor markers, which could be detected in easily accessible biological fluids, because they can be useful for screening and early diagnostics of cancer (before its clinical manifestation) as well as for verification of standard methods of diagnostics. Extracellular nucleic acids, circulating in blood (cirNA), are highlighted as the potential source of material for the early lung cancer diagnostics, prediction of antitumor treatment efficiency, post-treatment monitoring and disease prognosis.
该综述概述了不同肺癌标志物开发的主要方法，包括基因、表观遗传、蛋白质、转录组、蛋白质组、代谢和miRNA标志物。由于表观遗传变化是恶性转化中最早发生的事件之一，因此对甲基化标志物进行了深入讨论。特别关注微创肿瘤标志物，其可在易于获取的生物体液中检测到，因为它们可用于癌症的筛查和早期诊断（在临床表现之前）以及诊断标准方法的验证。血液中循环的细胞外核酸（cirNA）被强调为早期肺癌诊断、抗肿瘤治疗效果预测、治疗后监测和疾病预后的潜在材料来源。
